Indivior Pharmaceuticals, Inc. Common Stock (INDV) is a publicly traded Healthcare sector company. As of October 15, 2026, INDV trades at $33.62 with a market cap of $4.03B and a P/E ratio of 12.57. INDV moved -1.58% today. Year to date, INDV is -5.91%; over the trailing twelve months it is +33.47%. Its 52-week range spans $7.62 to $42.81. Analyst consensus is strong buy with an average price target of $45.50. Rallies surfaces INDV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Indivior shareholders approve Supernus merger, expected to close November 2: Indivior shareholders approved issuing common stock for the merger, with 94% of votes cast in favor; Supernus shareholders also adopted the merger agreement. The transaction is expected to close on November 2, 2026, and the combined company will operate as Supernus, Inc., trading on Nasdaq under SUPN.
| Metric | Value |
|---|---|
| Price | $33.62 |
| Market Cap | $4.03B |
| P/E Ratio | 12.57 |
| EPS | $2.88 |
| Dividend Yield | 8.13% |
| 52-Week High | $42.81 |
| 52-Week Low | $7.62 |
| Volume | 712.74K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.33B |
| Net Income | $355.00M |
| Gross Margin | 81.98% |
3 analysts cover INDV: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.50.